Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04965220
Status:
RECRUITING
Last Update Posted:
2023-08-09
First Post:
2021-06-09
Brief Title:
HLX208 BRAF V600E Inhibitor in Combination With Trametinib in Patients With Advanced Solid Tumors
Sponsor:
Shanghai Henlius Biotech
Organization:
Shanghai Henlius Biotech
Study Overview
Official Title:
A Phase I Clinical Trial Evaluating the Safety Tolerability Pharmacokinetics and Initial Efficacy of HLX208 BRAF V600E Inhibitor in Combination With Trametinib in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A phase I clinical trial evaluating the safety tolerability pharmacokinetics and initial efficacy of HLX208 BRAF V600E inhibitor in combination with trametinib in patients with advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None